InMed Pharmaceuticals (INM) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
InMed Pharmaceuticals (INM) Net Income towards Common Stockholders Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | -39.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -224.14% |
| Dec 31, 2025 | 21.23% |
| Sep 30, 2025 | -2.92% |
| Jun 30, 2025 | 32.33% |
| Mar 31, 2025 | 96.87% |
| Dec 31, 2024 | -74.20% |
| Sep 30, 2024 | 33.86% |
| Jun 30, 2024 | -473.57% |
| Mar 31, 2024 | 13.70% |
| Dec 31, 2023 | 29.55% |
| Sep 30, 2023 | 27.73% |
| Jun 30, 2023 | 95.72% |
| Mar 31, 2023 | 42.56% |
| Dec 31, 2022 | 51.01% |
| Sep 30, 2022 | -18.12% |